Lymphoma - Clinical Research
61 – 75 of 99
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
(
- Contribution to journal › Article
-
Mark
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
(
- Contribution to journal › Article
-
Mark
Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies
(
- Contribution to journal › Article
- 2018
-
Mark
Body composition measurements and risk of hematological malignancies : A population-based cohort study during 20 years of followup
(
- Contribution to journal › Article
-
Mark
Target Genes of WT1 in Leukemic Cells
2018) Scientific Symposium -European Academy for Biomedical Science(
- Contribution to conference › Poster
-
Mark
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
(
- Contribution to journal › Letter
-
Mark
Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
(
- Contribution to journal › Article
-
Mark
Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
(
- Contribution to journal › Article
-
Mark
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON) : A multicentre, open-label, single-arm, phase 2 trial
(
- Contribution to journal › Article
-
Mark
Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma : A critical assessment of the R-IPI, IPI, and NCCN-IPI
(
- Contribution to journal › Article
-
Mark
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of comorbidity on survival in peripheral T-cell lymphomas : A Swedish Lymphoma Registry study
(
- Contribution to journal › Article
- 2017
-
Mark
Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
(
- Contribution to journal › Article
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter